###### Key messages

What is the key question?
=========================

-   How much do respiratory viruses and bacteria contribute to community-acquired pneumonia in highly vaccinated children?

What is the bottom line?
========================

-   Many pneumonia-causing pathogens are also detected in asymptomatic children, thereby confounding our understanding to their contribution to pneumonia in children.

Why read on?
============

-   We conducted the largest age-frequency matched case--control study in a developed setting showing substantial contribution of respiratory syncytial virus, human metapneumovirus and *Mycoplasma pneumoniae* to all childhood pneumonia requiring hospitalisation in the post pneumococcal conjugate vaccine era.

Background {#s1}
==========

Pneumonia remains as a leading cause of hospitalisation and death among children worldwide, with nearly 120 million new cases and one million deaths annually, mostly among children aged under 5 years.[@R1] Although the greatest disease burden is in developing countries, pneumonia remains an important public health concern in developed countries where concerns are compounded by growing antibiotic resistance, replacement disease caused by vaccine-escape strains and the emergence of newly identified pathogens.[@R2] In Australia, there are two to eight pneumonia hospitalisations per 1000 child-years among children \<5 years old; Aboriginal children have more than a 10-fold higher risk than non-Aboriginal children.[@R4]

Globally, bacteria, particularly *Streptococcus pneumoniae* and encapsulated and non-encapsulated strains of *Haemophilus influenzae*, are considered as the primary cause of pneumonia in young children.[@R3] In recent years, there has been an increased focus on the role of respiratory viruses in childhood pneumonia, partly due to the reduction in bacterial disease associated with conjugate pneumococcal and Hib vaccine use[@R6] and the increased capacity to detect virus through molecular diagnostic methods. These sensitive techniques have enabled detection of viruses in up to 92% of respiratory specimens of children with pneumonia.[@R8] Many of the commonly detected respiratory viruses and bacteria are also detected in the nasopharynx of apparently healthy children, obscuring their exact contribution to childhood pneumonia.[@R9] Except for influenza vaccine, no licensed vaccines for common respiratory viruses are currently available although a number of vaccines for other respiratory viruses are in clinical trials.[@R16]

To date, few pneumonia aetiology studies from high-income settings seeking to quantify the exact contribution of pathogens to pneumonia have included healthy controls.[@R9] Well-controlled epidemiological studies have reported the contribution of respiratory viruses to childhood pneumonia in developing settings, but their findings are unlikely to be generalisable to settings with better developed health infrastructure, including better vaccine coverage.[@R15] We conducted a prospective case--control study to estimate the contribution of respiratory viruses and bacteria to childhood pneumonia in West Australian (WA) children, a highly vaccinated and high-income population.

Methods {#s2}
=======

This prospective case--control study was conducted from May 2015 through October 2017 following a published study protocol.[@R21]

Study population and data collection {#s2a}
------------------------------------

Cases were children aged \<18 years old who presented with community-acquired pneumonia (CAP) to the Princess Margaret Hospital (PMH), the only tertiary paediatric hospital for the state of Western Australia (population: 2.6 million[@R22]). WA children are highly vaccinated: pneumococcal conjugate vaccine (PCV) is funded on the national immunisation programme and coverage among infants is \>90%. Seasonal influenza vaccine is also funded for WA children aged 6 months to \<5 years and for older children with high-risk conditions.[@R23]

A diagnosis of CAP required: (1) the presence of acute respiratory symptoms (with or without fever) and (2) evidence of infiltrates or consolidation on chest X-ray.[@R24] A pragmatic definition of radiologically confirmed pneumonia (infiltrates or alveolar consolidation as determined by the treating clinician) facilitating recruitment after hours (ie, when a radiologist is not available to review the chest X-ray). An equal number of contemporaneous healthy controls attending hospital outpatient orthopaedics or allergy clinics or a large urban community immunisation clinic were enrolled. Children attending clinic with respiratory symptoms, following recent respiratory illnesses or those previously enrolled as a case or control were not eligible. Controls were enrolled concurrently with cases throughout the study period, with the target enrolment in each of four age groups (≤1 year, 1--5 years, 6--9 years and≥10 years) frequency-matched to the number of cases enrolled in the preceding 2 weeks. The sample size calculation for the study has been previously described.[@R21] A structured questionnaire was administered to parents/guardians to capture demography, relevant comorbidities including immunodeficiency, immunocompromised condition, congenital chromosomal abnormality, chronic respiratory, neuromuscular, neurological and cardiac disease and solid organ transplantation.

Specimen collection and microbiological assays {#s2b}
----------------------------------------------

A flocked nasopharyngeal swab (FLOQSwabs; Copan Diagnostics, Murrieta, California, USA) was collected from each participant by a trained research assistant; for cases, the swab was collected \<36 hours after hospital presentation. After collection, the swab was placed immediately into 1 mL Skim-Milk--Tryptone--Glucose--Glycerol--Broth on ice. All specimens were stored at −80°C prior to nucleic acid extraction. A total of 14 viruses (influenza A/H1N1 and A/H3N2, influenza B, respiratory syncytial virus (RSV), human parainfluenza virus (HPIV) type 1--3, human metapneumovirus (HMPV), adenovirus, rhinovirus (RV), human coronavirus (HCoV) types HCoVOC43, HCoV229E, HCoVHKU1 and HCoVNL63 and 6 bacteria (*S. pneumoniae*, *Staphylococcus aureus*, *Moraxella catarrhalis*, *H. influenzae*, *Mycoplasma pneumoniae* and *Chlamydophila pneumoniae*) were detected using polymerase chain reaction (PCR). Detailed procedures for laboratory testing for nucleic acid extraction and the primers and probes used in PCR have been described previously.[@R21] RV genotyping was done following published molecular methods.[@R25]

Data management and analysis {#s2c}
----------------------------

The crude odds ratio (OR) of exposure was calculated to assess the relative frequency of detection of each respiratory pathogen among cases and controls. Multivariate logistic regression was used to calculate the adjusted OR (aOR) of detection of each pathogen for cases versus controls, adjusting for underlying demographic differences, recent exposure to antibiotics and for the presence of other pathogens. The aOR for each pathogen was then used to estimate the population-attributable fraction (PAF).[@R26] Analyses were performed using STATA software, V.13.0, and figures were produced using GraphPad Prism, Version 5.0 (GraphPad Software, California, USA).

Ethical consideration {#s2d}
---------------------

Written informed consent was obtained from parents/legal guardians of all study participants. Assent was obtained from participants ≥7 years old.

Results {#s3}
=======

Characteristics of study population {#s3a}
-----------------------------------

We enrolled 230 children with pneumonia and 230 controls. Of 230 cases, 24 (10%) cases were diagnosed with a parapneumonic effusion with 21 (9%) parapneumonia effusions drained. All drained effusions had microscopic purulence consistent with empyema. Cases were hospitalised for a median of 2 days (IQR: 1--3); no deaths were observed. Compared with controls, a higher proportion of cases were Aboriginal, born premature and reported a smoker in the household (p\<0.001 for each) ([table 1](#T1){ref-type="table"}). The proportion of respondents \<5 years attending day care was 59.1% among cases (n=87) and 36.6% among controls (n=66), and the median days of attendance per week for cases was 3 days (IQR: 2--4) and for controls was 2 days (IQR: 2--3). A higher proportion of cases had comorbidities compared with controls (14.7% vs 4.3%, p\<0.001). More cases than controls had antibiotics in the 7 days prior enrolment (47.3% vs 2.1%, p\<0.001). The proportion of cases and controls who had received at least two doses of PCV was 91.3% and 87.8%, respectively, and 10.4% of both cases and controls had received influenza vaccine in the preceding influenza season.

###### 

Characteristics of children with community-acquired pneumonia (cases) and healthy children (controls), Perth, Western Australia, May 2015--October 2017

  Parameter                                  Case (%), (n=230)   Control (%), (n=230)   Total (%), (N=460)
  ------------------------------------------ ------------------- ---------------------- --------------------
  Demographic and clinical data                                                         
   Age                                                                                  
    ≤12 months                               21 (9.1)            23 (10)                44 (9.5)
    1--5 years                               126 (54.7)          157 (68.2)             283 (61.5)
    6--9 years                               60 (26.1)           27 (11.7)              87 (18.9)
    10+ years                                23 (10)             23 (10)                46 (10)
   Male sex                                  120 (52.1)          122 (53.0)             242 (52.6)
   Aboriginal\*                              21 (9.1)            2 (0.8)                23 (5.0)
   Premature\*                               32 (13.9)           17 (7.3)               49 (10.6)
   Smoker at household\*                     38 (16.5)           22 (9.5)               60 (13.0)
  Existing health conditions†                                                           
   Any comorbidity                           34 (14.7)           10 (4.3)               44 (9.5)
    Immunodeficiency                         7 (3.0)             1 (0.4)                8 (1.7)
    Immunocompromised condition              5 (2.1)             0 (0.0)                5 (1.1)
    Congenital chromosomal abnormality       16 (6.9)            4 (1.7)                20 (4.3)
    Chronic respiratory illness              9 (3.9)             2 (0.8)                11 (2.3)
    Chronic neuromuscular disorder illness   9 (3.9)             2 (0.8)                11 (2.3)

\*P value \<0.001 for difference between cases and controls.

†No child had an organ transplant, one case had chronic cardiac disease and one case had an intracranial shunt.

Respiratory viruses and bacteria associated with pneumonia {#s3b}
----------------------------------------------------------

Of 230 cases and 230 controls, one or more respiratory viruses were identified in 56.5% and 28.6%, respectively (OR: 3.2; 95% CI: 2.1 to 4.7), and at least one bacterial species was detected in 71.7% and 79.5%, respectively (OR: 0.6; 95% CI: 0.4 to 1.0). The distribution of respiratory viruses and bacteria among cases and controls is summarised in [table 2](#T2){ref-type="table"}. Detection of both viruses and bacteria was observed in 104 cases (45.2%) and in 56 controls (24.3%). Cases were more likely than controls to have multiple (two or more) viruses detected (OR: 5.1, 95% CI: 1.7 to 15.1) but not multiple bacterial species (OR: 1.0, 95% CI: 0.7 to 1.4).

###### 

Distribution of respiratory pathogens in children with CAP (cases) and healthy children (controls), unadjusted and adjusted OR and population-attributable fraction for each respiratory pathogen, Perth, Western Australia, May 2015--October 2017

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Parameter                                      Case (%),\   Control (%),\   Unadjusted OR\        Adjusted OR\           Population-attributable fraction estimate, % (95% CI)
                                                 (n=230)      (n=230)         (95% CI)              (95% CI)\*             
  ---------------------------------------------- ------------ --------------- --------------------- ---------------------- -------------------------------------------------------
  Respiratory virus                                                                                                        

   Influenza (any)                               16 (6.9)     3 (1.3)         5.6 (1.6 to 19.6)     10.1 (1.8 to 57.1)     6.2 (2.5 to 9.7)

    Influenza A H1N1                             4 (1.7)      1 (0.4)         4.0 (0.4 to 36.5)     23.1 (1.2 to 442.6)    

    Influenza A H3                               9 (3.9)      1 (0.4)         9.3 (1.1 to 74.2)     9.6 (0.7 to 119.7)     

    Influenza B                                  3 (1.3)      1 (0.4)         3.0 (0.3 to 29.3)     2.7 (0.1 to 43.9)      

   RSV                                           46 (20.0)    3 (1.3)         18.9 (5.7 to 61.8)    58.4 (15.6 to 217.5)   20.2 (14.6 to 25.5)

   HPIV (any)                                    11 (4.7)     0               --                    --                     --

    HPIV1                                        6 (2.6)      0               --                    --                     --

    HPIV2                                        0            0               --                    --                     --

    HPIV3                                        5 (2.1)      0               --                    --                     --

   Rhinovirus                                    35 (15.2)    48 (20.8)       0.7 (0.4 to 1.1)      1.3 (0.6 to 2.6)       3.6 (- 0.05 to 12.2)

   HMPV                                          23 (10)      2 (0.8)         12.6 (2.9 to 54.3)    37.2 (7.8 to 177.7)    9.8 (5.6 to 13.7)

   Adenovirus                                    10 (4.3)     3 (1.3)         3.4 (0.9 to 12.6)     12.1 (1.4 to 104.4)    4 (1.1 to 7.1)

   Coronavirus (any)                             8 (3.4)      11 (4.7)        0.7 (0.2 to 1.8)      0.8 (0.1 to 4.4)       

    Coronavirus OC43                             5 (2.1)      3 (1.3)         0.6 (0.1 to 2.5)      0.7 (0.1 to 3.9)       

    Coronavirus NL63                             4 (1.7)      3 (1.3)         1.3 (0.3 to 6.0)      1.5 (0.1 to 21.8)      

    Coronavirus HKU1                             1 (0.4)      2 (0.8)         0.5 (0.04 to 5.5)     0.5 (0.0 to 2724.1)    

    Coronavirus 229E                             0            1 (0.4)         --                    --                     

   At least one respiratory virus identified     130 (56.5)   66 (28.6)       3.2 (2.1 to 4.7)      4.7 (2.8 to 7.8)       44.4 (33.8 to 53.3)

    One virus                                    111 (48.2)   62 (26.9)                                                    

    Two or more viruses                          19 (8.2)     4 (1.7)                                                      

  Bacteria                                                                                                                 

   *Streptococcus pneumoniae*                    59 (25.3)    61 (26.5)       0.9 (0.6 to 1.4)      0.6 (0.3 to 1.4)       

   *Haemophilus influenzae*                      75 (32.6)    61 (26.5)       1.3 (0.8 to 2.0)      0.9 (0.4 to 1.7)       

   *Moraxella catarrhalis*                       103 (44.7)   144 (62.6)      0.4 (0.3 to 0.7)      0.6 (0.3 to 1.1)       

   *Staphylococcus aureus*                       38 (16.5)    36 (15.6)       1.0 (0.6 to 1.7)      1.3 (0.6 to 2.9)       

   *Mycoplasma pneumoniae*                       19 (8.2)     1 (0.4)         20.6 (2.7 to 155.3)   14.5 (2.2 to 94.8)     7.2 (3.5 to 10.8)

   *Chlamydophila pneumoniae*                    0            1 (0.4)         --                                           

   At least one species of bacteria identified   165 (71.7)   183 (79.5)      0.6 (0.4 to 1.0)      0.7 (0.4 to 1.2)       

    One bacteria                                 69 (30.0)    88 (38.2)                                                    

    Two or more bacterial species                96 (41.7)    95 (41.3)                                                    
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Adjusted for age group, gender, prematurity, aboriginal status, comorbidity, childcare attendance, smoker at household, antibiotic exposure in last 7 days of enrolment and presence of other pathogens.

CAP, community-acquired pneumonia; HMPV, human metapneumovirus; HPIV, human parainfluenza virus; RSV, respiratory syncytial virus.

Viral pathogens {#s3c}
---------------

The multivariate logistic regression showed that after adjusting for demographic differences, antibiotic exposure in the preceding 7 days, and presence of other pathogens, RSV, HMPV, influenza virus and adenovirus were detected significantly more often among cases than controls with aOR 58.4 (95% CI: 15.6 to 217.5), 37.2 (95% CI: 7.8 to 177.7), 10.1 (95% CI: 1.8 to 57.1) and 12.1 (95% CI: 1.4 to 104.4), respectively ([table 2](#T2){ref-type="table"}). None of the influenza-positive cases (n=16) or controls (n=3) had received influenza vaccine during the preceding influenza season. RV speciation was available for 57 (69%) of 83 positive samples (26 cases; 31 controls). RV-A was detected in 13 cases (50%) and 15 controls (48.3%), RV-B in 1 (3.8%) case and 2 (6.4%) controls and RV-C was detected in 12 (46.1%) cases and 14 (45.1%) controls.

Respiratory viruses were detected more commonly among children \<5 years compared with other age groups ([figure 1](#F1){ref-type="fig"}). More than 75% of cases positive for RSV, HPIV, HMPV and adenovirus were aged less than 3 years. Respiratory viruses were detected throughout the year with frequent detection during the Australian winter months (June to August). RV was detected throughout the year, while RSV, influenza and HMPV were mostly detected between May and November and HPIV between December and April; virus distribution among cases and control children was similar along the year calendar ([figures 2 and 3](#F2 F3){ref-type="fig"}).

![Distribution of respiratory pathogens by participant's age (in months); dot lines refers to age-group breakdown among study participants; for bacteria, such as *Haemophilus influenzae* (Hi), *Streptococcus pneumoniae* (Sp), *Moraxella catarrhalis* (Mc) and *Staphylococcus aureus* (Sau), only children without prior antibiotic exposure were included and *Mycoplasma pneumoniae* (Mp) included all children.](thoraxjnl-2018-212096f01){#F1}

![Distribution of respiratory viruses in the nasopharynx of children with community-acquired pneumonia (case group), by seasons, Perth, Western Australia, May 2015--October 2017. HMPV, human metapneumovirus; HPIV, human parainfluenza virus; RSV, respiratory syncytial virus.](thoraxjnl-2018-212096f02){#F2}

![Distribution of respiratory viruses in the nasopharynx of healthy children (control group), by seasons, Perth, Western Australia, May 2015--October 2017. HMPV, human metapneumovirus; HPIV, human parainfluenza virus; RSV, respiratory syncytial virus.](thoraxjnl-2018-212096f03){#F3}

Bacterial pathogens {#s3d}
-------------------

The multivariate logistic regression showed *M. pneumoniae* were detected significantly more often among cases than controls with aOR 14.5 (95% CI: 2.2 to 94.8). The frequency of detection of other bacteria was similar among cases and controls ([table 2](#T2){ref-type="table"}).

Nineteen (32.1%) of 59 cases with *S. pneumoniae* detected had prior antibiotic exposure compared with 1 (1.6%) of 61 controls; for *H. influenzae*, the proportion was 45.3% (34/75) in cases and 3.2% (2/61) in controls; for *M. catarrhalis*, 29.1% (30/103) in cases and 2.0% (3/144) in controls; for *S. aureus*, 36.8% (14/38) in cases and 0% (0/36) in controls and for *M. pneumoniae,* 89.4% (17/19) in cases and 0% (0/1) in controls. Given the potential for antibiotics to influence the detection of bacterial pathogens, the analysis was repeated including only those with no prior antibiotic exposure: apart from *M. pneumoniae* (aOR 16.7; 95% CI: 1.6 to 164.8), no significant difference in *S. pneumoniae* (aOR 0.6; 95% CI: 0.2 to 1.3), H. *influenzae* (aOR 0.9; 95% CI: 0.4 to 1.8), *M. catarrhalis* (aOR 0.7; 95% CI: 0.4 to 1.4) and *S. aureus* (aOR 1.5; 95% CI: 0.7 to 3.5) detection was noted.

Among children with no prior antibiotic exposure, few differences were noted in the age-group distribution of bacterial detection ([figure 1](#F1){ref-type="fig"}). Among infants (aged \<1 year), more cases than controls were positive for *S. pneumoniae* (6/15, 40% vs 2/23, 8.7%, p=0.02). *M. pneumoniae* was detected more commonly in school-aged children than in younger children. *M. catarrhalis* was detected throughout the year, whereas *S. pneumoniae*, *H. influenzae*, *S. aureus* and *M. pneumoniae* were detected more commonly in winter months ([figures 4 and 5](#F4 F5){ref-type="fig"}).

![Distribution of bacteria in the nasopharynx of children with community-acquired pneumonia (case group), by seasons, Perth, Western Australia, May 2015--October 2017.](thoraxjnl-2018-212096f04){#F4}

![Distribution of bacteria in the nasopharynx of healthy children (control group), by seasons, Perth, Western Australia, May 2015--October 2017.](thoraxjnl-2018-212096f05){#F5}

Population-attributable fraction {#s3e}
--------------------------------

We estimated that detectable respiratory viruses are responsible for 44.4% (95 % CI: 33.8% to 53.3%) of all childhood pneumonia in Western Australia ([table 2](#T2){ref-type="table"}). RSV contributed nearly half of this burden (20.2%, 95% CI: 14.6% to 25.5%) with HMPV contributing 9.8% (95% CI: 5.6% to 13.7%), influenza 6.2% (95% CI: 2.5% to 9.7%) and adenovirus 4.0% (95% CI: 1.1% to 7.1%). The only detectable bacteria that could be shown to make a significant contribution to childhood pneumonia in our population was *M. pneumoniae* (7.2%, 95% CI: 3.5% to 10.8%). We were not sufficiently powered to estimate age group-specific PAF for these pathogens.

Discussion {#s4}
==========

Respiratory viruses appear to contribute significantly to childhood pneumonia in Western Australia. By prospectively enrolling and testing children hospitalised with radiologically confirmed pneumonia and contemporaneous healthy children, we were able to assess the contribution of common respiratory viruses and bacteria to pneumonia adjusting for the background prevalence of detection in children without pneumonia. We estimate that detectable respiratory viruses contribute approximately 44% of all childhood pneumonia requiring hospitalisation.

Respiratory viruses were detected in the nasopharynx of 57% of children with pneumonia, which is comparable to the frequency of virus detection in other paediatric pneumonia studies.[@R11] Similar to previous studies, we were also able to detect respiratory viruses in the nasopharynx of nearly one-third of controls.[@R11] In another matched case--control study, viruses were detected more frequently (in 86% of cases and 55% of controls); that study only enrolled children during winter months when respiratory virus circulation is likely to be greater.[@R9]

RSV was the most frequently detected virus in children with pneumonia and was most common in children \<2 years. The proportion of children with pneumonia in whom RSV was detected was consistent with that reported in previous studies.[@R8] In contrast, few control children in our study were RSV positive (3%), also consistent with the published literature.[@R11] Another member from the paramyxoviridae family, HMPV, was detected in 10% of cases but infrequently detected in healthy controls. The high adjusted OR for the detection of RSV and HMPV in children with pneumonia strongly implicates these viruses as probable pneumonia-causing pathogens. RSV is well established as a major cause of lower respiratory tract infection.[@R31] This study adds to the growing evidence that HMPV is also an important respiratory pathogen in young children.[@R9]

Children with pneumonia were also more likely to have influenza detected. Influenza is well documented to cause severe and occasionally fatal respiratory infection.[@R34] All influenza-positive cases and controls were unvaccinated. Low influenza vaccination has been reported among children with influenza-confirmed pneumonia previously.[@R35] Consistent with a protective effect, improved uptake of seasonal influenza vaccine in children is likely to reduce hospitalisations for pneumonia. RV was detected in similar proportions of children with (15%) and without (21%) pneumonia. Previous studies also detected RV in both children with pneumonia[@R9] as well as in apparently asymptomatic children.[@R14] The latter raises doubt about the contribution of RV in pneumonia.[@R37]Our finding is in line with other case--control studies that also failed to show the significant contribution of RV in acute respiratory infections in children.[@R9] While RV, particularly RV-C, has been associated with childhood wheezing and asthma,[@R39] its role in childhood pneumonia is not established. We had insufficient numbers to determine any specific RV types to be more prevalent among cases than controls; a study among Burundian children with lower respiratory tract symptoms associated RV-A with pneumonia and RV-C with wheezing.[@R40] However, recently, using advanced molecular techniques such as transcriptomic analysis, a robust immune response had been measured in symptomatic children with detectable RV, substantially higher than in asymptomatic RV-positive children,[@R41] suggesting the role of RV in acute respiratory infection needs more exploration.

*M. pneumoniae* was detected with similar frequency among cases to that reported in previous pneumonia studies and particularly prevalent among school-aged children and adolescents.[@R8] Unlike other studies,[@R42] *M. pneumoniae* was identified infrequently in the nasopharynx of our control subjects.[@R11] *M. pneumoniae* most frequently causes non-severe atypical pneumonia. Detection of *M. pneumoniae* in the nasopharynx is reported in asymptomatic children, making it further difficult to interpret their clinical role in pneumonia. Moreover, there are conflicting and inconclusive reports on appropriate treatment for *M. pneumoniae*. Recent reviews and meta-analysis concluded that there is insufficient evidence on the efficacy of single or combination of multiple antibiotic for lower respiratory tract infections in children associated with *M. pneumoniae*.[@R43]

*S. pneumoniae*, *H. influenzae* and *M. catarrhalis* were detected with similar frequency in children with and without pneumonia. However, high vaccine coverage has almost eliminated pathogenic vaccine-type strains of *S. pneumoniae* and *H. influenzae* in this population.[@R6] While there were no differences overall, *S. pneumoniae* was detected more frequently among infants with pneumonia than in control infants, suggesting *S. pneumoniae* may remain as an important cause of pneumonia in early life. While our results suggest a lesser contribution of bacteria to childhood pneumonia than viruses, we caution that we have not disproved an important role for bacteria. It is plausible, for example, that secondary bacterial infection plays an important role in many cases of viral pneumonia.[@R34]

A major strength of our study was the contemporaneous enrolment of children without pneumonia who were frequency-matched by age to pneumonia cases throughout the study period, which addressed methodological limitations in previous case--control studies in developed settings during post pneumococcal vaccination era.[@R9] However, our study has some limitations. To detect respiratory viruses and bacteria, we collected biological specimens from the upper respiratory tract (nasopharynx). The diagnosis of probable infectious agents associated with the lower respiratory tract illness such as pneumonia in children is often based on minimally invasive nasopharyngeal aspirates or nose/throat swabs.[@R9] Testing of specimens from usually sterile sites (including blood and pleural fluid for culture or PCR) is available in our setting but was not mandated by our protocol. It is to be noted that while detecting a pathogen in the upper respiratory tract is not conclusive of its causal association with disease; however, testing control children without pneumonia enabled us to have a better estimation on contribution to pneumonia at the population level. Our ability to identify respiratory pathogens associated with pneumonia was limited by the sensitivity of testing the specimens from nasopharynx for infection in the lower airways. Differences between pathogen detection in the upper and lower tract have been shown previously[@R47]; it is plausible that in some cases with detectable virus, shedding of virus from the nasopharynx might be insignificant, or that shedding might be waning by the time children are hospitalised with pneumonia. Because of the sensitivity of our testing methods is likely incomplete, we expect that these estimates of the contribution of viruses to pneumonia represent minimum estimates. We used qualitative PCR assays in this study; determination of pathogen density through quantitative assays may permit distinction of causative from coincidental infection in particular cases of pneumonia.[@R48] We did not collect but data on radiographic details, for example, lobar consolidation or intestinal infiltrate, of enrolled cases would be useful to assess if radiographic pattern is associated with pathogen (bacterial or viral or both) detected in nasopharynx.

The burden of childhood pneumonia could be reduced if effective vaccines and treatments targeting viruses were readily available.[@R49] Understanding the contribution of each virus to pneumonia is important to informing and prioritising vaccine development. Australia has well-established health infrastructure with high rates of vaccine coverage. The findings of our study are expected to be generalisable to similar developed settings but not necessarily to resource-poor settings countries with high crowding, different social mixing patterns and low vaccine coverage. Nonetheless, we note that our data are comparable to data from case--control studies from both high-income and middle- and low-income countries.[@R15]

This is the most comprehensive study that described contribution of respiratory pathogens to childhood pneumonia in Australia to date and one of few case--control studies on childhood pneumonia from high-income settings in the PCV era. We found that respiratory viruses are a major contributor to childhood pneumonia. RSV appeared to account for a substantial proportion of viral pneumonia and should continue to be a focus for the development of preventative and treatment strategies. The burden of HMPV pneumonia may have been underappreciated before now. Data from this study could serve as baseline characteristics to assess the effectiveness of viral vaccines after their availability. Future studies should aim to develop a precise diagnostic tool that reliably distinguish viral from bacterial pneumonia to allow for targeted antiviral therapies and the more judicious use of antibiotics in treating childhood pneumonia.
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